|
1
|
Ferlay J, Soerjomataram I, Ervik M, et al:
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11 (Internet). Lyon, France: International Agency
for Research on Cancer; 2013, Available from: http://globocan.iarc.fr.
Accessed.
|
|
2
|
Kanu OO, Mehta A, Di C, Lin N, et al:
Glioblastoma multiforme: a review of therapeutic targets. Expert
Opin Ther Targets. 13:701–718. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gazzerro P, Proto MC, Gangemi G, et al:
Pharmacological actions of statins: a critical appraisal in the
management of cancer. Pharmacol Rev. 64:102–146. 2012. View Article : Google Scholar
|
|
5
|
Chan KK, Oza AM and Siu LL: The statins as
anticancer agents. Clin Cancer Res. 9:10–19. 2003.PubMed/NCBI
|
|
6
|
Baserga R: Molecular biology of the cell
cycle. Int J Radiat Biol Relat Stud Phys Chem Med. 49:219–226.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tapia-Pérez JH, Kirches E, Mawrin C,
Firsching R and Schneider T: Cytotoxic effect of different statins
and thiazolidinediones on malignant glioma cells. Cancer Chemother
Pharmacol. 67:1193–1201. 2011. View Article : Google Scholar
|
|
8
|
Rao S, Lowe M, Herliczek TW and Keyomarsi
K: Lovastatin mediated G1 arrest in normal and tumor breast cells
is through inhibition of CDK2 activity and redistribution of p21
and p27, independent of p53. Oncogene. 17:2393–2402. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Collisson EA, Kleer C, Wu M, et al:
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis
in human melanoma cells. Mol Cancer Ther. 2:941–948.
2003.PubMed/NCBI
|
|
10
|
Agarwal B, Bhendwal S, Halmos B, Moss SF,
Ramey WG and Holt PR: Lovastatin augments apoptosis induced by
chemotherapeutic agents in colon cancer cells. Clin Cancer Res.
5:2223–2229. 1999.PubMed/NCBI
|
|
11
|
Marcelli M, Cunningham GR, Haidacher SJ,
et al: Caspase-7 is activated during lovastatin-induced apoptosis
of the prostate cancer cell line LNCaP. Cancer Res. 58:76–83.
1998.PubMed/NCBI
|
|
12
|
Koyuturk M, Ersoz M and Altiok N:
Simvastatin induces apoptosis in human breast cancer cells: p53 and
estrogen receptor independent pathway requiring signalling through
JNK. Cancer Lett. 250:220–228. 2007. View Article : Google Scholar
|
|
13
|
Baetta R, Donetti E, Comparato C, et al:
Pro-apoptotic effect of atorvastatin on stimulated rabbit smooth
muscle cells. Pharmacol Res. 36:115–121. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang IK, Lin-Shiau SY and Lin JK:
Induction of apoptosis by lovastatin through activation of
caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol.
86:83–91. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He Z, Mangala LS, Theriot CA, Rohde LH, Wu
H and Zhang Y: Cell killing and radiosensitizing effects of
atorvastatin in PC3 prostate cancer cells. J Radiat Res.
53:225–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Denoyelle C, Vasse M, Körner M, et al:
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the
signaling pathways involved in the invasiveness and metastatic
properties of highly invasive breast cancer cell lines: an in vitro
study. Carcinogenesis. 22:1139–1148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bouterfa HL, Sattelmeyer V, Czub S,
Vordermark D, Roosen K and Tonn JC: Inhibition of Ras farnesylation
by lovastatin leads to downregulation of proliferation and
migration in primary cultured human glioblastoma cells. Anticancer
Res. 20:2761–2771. 2000.PubMed/NCBI
|
|
18
|
Schmidmaier R, Baumann P, Bumeder I,
Meinhardt G, Straka C and Emmerich B: First clinical experience
with simvastatin to overcome drug resistance in refractory multiple
myeloma. Eur J Haematol. 79:240–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sondergaard TE, Pedersen PT, Andersen TL,
et al: A phase II clinical trial does not show that high dose
simvastatin has beneficial effect on markers of bone turnover in
multiple myeloma. Hematol Oncol. 27:17–22. 2009. View Article : Google Scholar
|
|
20
|
Bjarnadottir O, Romero Q, Bendahl PO, et
al: Targeting HMG-CoA reductase with statins in a
window-of-opportunity breast cancer trial. Breast Cancer Res Treat.
138:499–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garwood ER, Kumar AS, Baehner FL, et al:
Fluvastatin reduces proliferation and increases apoptosis in women
with high grade breast cancer. Breast Cancer Res Treat.
119:137–144. 2010. View Article : Google Scholar
|
|
22
|
Inano H, Suzuki K, Onoda M and Wakabayashi
K: Anti-carcinogenic activity of simvastatin during the promotion
phase of radiation-induced mammary tumorigenesis of rats.
Carcinogenesis. 18:1723–1727. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Narisawa T, Fukaura Y, Tanida N, Hasebe M,
Ito M and Aizawa R: Chemopreventive efficacy of low dose of
pravastatin, an HMG-CoA reductase inhibitor, on
1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice.
Tohoku J Exp Med. 180:131–138. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Narisawa T, Morotomi M, Fukaura Y, Hasebe
M, Ito M and Aizawa R: Chemoprevention by pravastatin, a
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of
N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.
Jpn J Cancer Res. 87:798–804. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clutterbuck RD, Millar BC, Powles RL, et
al: Inhibitory effect of simvastatin on the proliferation of human
myeloid leukaemia cells in severe combined immunodeficient (SCID)
mice. Br J Haematol. 102:522–527. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kikuchi T, Nagata Y and Abe T: In vitro
and in vivo antiproliferative effects of simvastatin, an HMG-CoA
reductase inhibitor, on human glioma cells. J Neurooncol.
34:233–239. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hawk MA, Cesen KT, Siglin JC, Stoner GD
and Ruch RJ: Inhibition of lung tumor cell growth in vitro and
mouse lung tumor formation by lovastatin. Cancer Lett. 109:217–222.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matar P, Rozados VR, Binda MM, Roggero EA,
Bonfil RD and Scharovsky OG: Inhibitory effect of lovastatin on
spontaneous metastases derived from a rat lymphoma. Clin Exp
Metastasis. 17:19–25. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matar P, Rozados VR, Roggero EA and
Scharovsky OG: Lovastatin inhibits tumor growth and metastasis
development of a rat fibrosarcoma. Cancer Biother Radiopharm.
13:387–393. 1998. View Article : Google Scholar
|
|
30
|
Alonso DF, Farina HG, Skilton G, Gabri MR,
De Lorenzo MS and Gomez DE: Reduction of mouse mammary tumor
formation and metastasis by lovastatin, an inhibitor of the
mevalonate pathway of cholesterol synthesis. Breast Cancer Res
Treat. 50:83–93. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Broitman SA, Wilkinson JT IV, Cerda S and
Branch SK: Effects of monoterpenes and mevinolin on murine colon
tumor CT-26 in vitro and its hepatic ‘metastases’ in vivo. Adv Exp
Med Biol. 401:111–130. 1996. View Article : Google Scholar
|
|
32
|
Jani JP, Specht S, Stemmler N, et al:
Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an
inhibitor of cholesterol biosynthesis. Invasion Metastasis.
13:314–324. 1993.PubMed/NCBI
|
|
33
|
Feleszko W, Mlynarczuk I, Balkowiec-Iskra
EZ, et al: Lovastatin potentiates antitumor activity and attenuates
cardiotoxicity of doxorubicin in three tumor models in mice. Clin
Cancer Res. 6:2044–2052. 2000.PubMed/NCBI
|
|
34
|
Feleszko W, Bałkowiec EZ, Sieberth E, et
al: Lovastatin and tumor necrosis factor-α exhibit potentiated
antitumor effects against Ha-ras-transformed murine tumor via
inhibition of tumor-induced angiogenesis. Int J Cancer. 81:560–567.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mucci LA and Stampfer MJ: Mounting
evidence for prediagnostic use of statins in reducing risk of
lethal prostate cancer. J Clin Oncol. 32:1–2. 2014. View Article : Google Scholar
|
|
36
|
Platz EA, Leitzmann MF, Visvanathan K, et
al: Statin drugs and risk of advanced prostate cancer. J Natl
Cancer Inst. 98:1819–1825. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jespersen CG, Norgaard M, Friis S, Skriver
C and Borre M: Statin use and risk of prostate cancer: a Danish
population-based case-control study, 1997–2010. Cancer Epidemiol.
38:42–47. 2014. View Article : Google Scholar
|
|
38
|
Yu O, Eberg M, Benayoun S, et al: Use of
statins and the risk of death in patients with prostate cancer. J
Clin Oncol. 32:5–11. 2014. View Article : Google Scholar
|
|
39
|
Geybels MS, Wright JL, Holt SK, Kolb S,
Feng Z and Stanford JL: Statin use in relation to prostate cancer
outcomes in a population-based patient cohort study. Prostate.
73:1214–1222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ferris JS, McCoy L, Neugut AI, Wrensch M
and Lai R: HMG CoA reductase inhibitors, NSAIDs and risk of glioma.
Int J Cancer. 131:E1031–E1037. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gaist D, Andersen L, Hallas J, Sørensen
HT, Schroder HD and Friis S: Use of statins and risk of glioma: a
nationwide case-control study in Denmark. Br J Cancer. 108:715–720.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsibouris P, Vlachou E and Isaacs PE: Role
of chemoprophylaxis with either NSAIDs or statins in patients with
Barrett’s esophagus. World J Gastrointest Pharmacol Ther. 5:27–39.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singh S, Singh AG, Singh PP, Murad MH and
Iyer PG: Statins are associated with reduced risk of esophageal
cancer, particularly in patients with Barrett’s esophagus: a
systematic review and meta-analysis. Clin Gastroenterol Hepatol.
11:620–629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Beales IL, Hensley A and Loke Y: Reduced
esophageal cancer incidence in statin users, particularly with
cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther.
4:69–79. 2013.PubMed/NCBI
|
|
45
|
Wu XD, Zeng K, Xue FQ, Chen JH and Chen
YQ: Statins are associated with reduced risk of gastric cancer: a
meta-analysis. Eur J Clin Pharmacol. 69:1855–1860. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lytras T, Nikolopoulos G and Bonovas S:
Statins and the risk of colorectal cancer: an updated systematic
review and meta-analysis of 40 studies. World J Gastroenterol.
20:1858–1870. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brewer TM, Masuda H, Liu DD, et al: Statin
use in primary inflammatory breast cancer: a cohort study. Br J
Cancer. 109:318–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
McDougall JA, Malone KE, Daling JR,
Cushing-Haugen KL, Porter PL and Li CI: Long-term statin use and
risk of ductal and lobular breast cancer among women 55 to 74 years
of age. Cancer Epidemiol Biomarkers Prev. 22:1529–1537. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Undela K, Srikanth V and Bansal D: Statin
use and risk of breast cancer: a meta-analysis of observational
studies. Breast Cancer Res Treat. 135:261–269. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lavie O, Pinchev M, Rennert HS, Segev Y
and Rennert G: The effect of statins on risk and survival of
gynecological malignancies. Gynecol Oncol. 130:615–619. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu W, Choueiri TK and Cho E: Statin use
and the risk of renal cell carcinoma in 2 prospective US cohorts.
Cancer. 118:797–803. 2012. View Article : Google Scholar
|
|
52
|
Singh S, Singh PP, Singh AG, Murad MH and
Sanchez W: Statins are associated with a reduced risk of
hepatocellular cancer: a systematic review and meta-analysis.
Gastroenterology. 144:323–332. 2013. View Article : Google Scholar
|
|
53
|
Pradelli D, Soranna D, Scotti L, et al:
Statins and primary liver cancer: a meta-analysis of observational
studies. Eur J Cancer Prev. 22:229–234. 2013. View Article : Google Scholar
|
|
54
|
Bonovas S, Filioussi K and Sitaras NM:
Statins are not associated with a reduced risk of pancreatic cancer
at the population level, when taken at low doses for managing
hyper-cholesterolemia: evidence from a meta-analysis of 12 studies.
Am J Gastroenterol. 103:2646–2651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cui X, Xie Y, Chen M, et al: Statin use
and risk of pancreatic cancer: a meta-analysis. Cancer Causes
Control. 23:1099–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Deng Z, Zhang S, Yi L and Chen S: Can
statins reduce risk of lung cancer, especially among elderly
people? A meta-analysis. Chin J Cancer Res. 25:679–688. 2013.
|
|
57
|
Tan M, Song X, Zhang G, et al: Statins and
the risk of lung cancer: a meta-analysis. PLoS One. 8:e573492013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li X, Wu XB and Chen Q: Statin use is not
associated with reduced risk of skin cancer: a meta-analysis. Br J
Cancer. 110:802–807. 2014. View Article : Google Scholar :
|
|
59
|
da Silva RD, Xylinas E, Kluth L, et al:
Impact of statin use on oncologic outcomes in patients with
urothelial carcinoma of the bladder treated with radical
cystectomy. J Urol. 190:487–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang XL, Geng J, Zhang XP, et al: Statin
use and risk of bladder cancer: a meta-analysis. Cancer Causes
Control. 24:769–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chan TF, Wu CH, Lin CL and Yang CY: Statin
use and the risk of breast cancer: a population-based case-control
study. Expert Opin Drug Saf. 13:287–293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chan TF, Chiu HF, Wu CH, Lin CL and Yang
CY: Statin use and the risk of esophageal cancer: a
population-based case-control study. Expert Opin Drug Saf.
12:293–298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kuo CC, Chiu HF, Lee IM, Kuo HW, Lee CT
and Yang CY: Statin use and the risk of bladder cancer: a
population-based case-control study. Expert Opin Drug Saf.
11:733–738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chiu HF, Kuo CC, Kuo HW, Lee IM, Lee CT
and Yang CY: Statin use and the risk of kidney cancer: a
population-based case-control study. Expert Opin Drug Saf.
11:543–549. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cheng MH, Chiu HF, Ho SC and Yang CY:
Statin use and the risk of female lung cancer: a population-based
case-control study. Lung Cancer. 75:275–279. 2012. View Article : Google Scholar
|
|
66
|
Nielsen SF, Nordestgaard BG and Bojesen
SE: Statin use and reduced cancer-related mortality. N Engl J Med.
367:1792–1802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Cholesterol Treatment Trialists’ (CTT)
Collaboration. Emberson JR, Kearney PM, Blackwell L, et al: Lack of
effect of lowering LDL cholesterol on cancer: meta-analysis of
individual data from 175,000 people in 27 randomised trials of
statin therapy. PLoS One. 7:e298492012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Larner J, Jane J, Laws E, Packer R, Myers
C and Shaffrey M: A phase I–II trial of lovastatin for anaplastic
astrocytoma and glioblastoma multiforme. Am J Clin Oncol.
21:579–583. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Thibault A, Samid D, Tompkins AC, et al:
Phase I study of lovastatin, an inhibitor of the mevalonate
pathway, in patients with cancer. Clin Cancer Res. 2:483–491.
1996.PubMed/NCBI
|
|
70
|
Hus M, Grzasko N, Szostek M, et al:
Thalidomide, dexamethasone and lovastatin with autologous stem cell
transplantation as a salvage immunomodulatory therapy in patients
with relapsed and refractory multiple myeloma. Ann Hematol.
90:1161–1166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lee J, Jung KH, Park YS, et al:
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin
(FOLFIRI) as first-line chemotherapy in metastatic colorectal
patients: a multicenter phase II study. Cancer Chemother Pharmacol.
64:657–663. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Han JY, Lee SH, Yoo NJ, et al: A
randomized phase II study of gefitinib plus simvastatin versus
gefitinib alone in previously treated patients with advanced
non-small cell lung cancer. Clin Cancer Res. 17:1553–1560. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hong JY, Nam EM, Lee J, et al: Randomized
double-blinded, placebo-controlled phase II trial of simvastatin
and gemcitabine in advanced pancreatic cancer patients. Cancer
Chemother Pharmacol. 73:125–130. 2014. View Article : Google Scholar
|
|
74
|
Limburg PJ, Mahoney MR, Ziegler KL, et al:
Randomized phase II trial of sulindac, atorvastatin, and prebiotic
dietary fiber for colorectal cancer chemoprevention. Cancer Prev
Res. 4:259–269. 2011. View Article : Google Scholar
|
|
75
|
Manoukian GE, Tannir NM, Jonasch E, Qiao
W, Haygood TM and Tu SM: Pilot trial of bone-targeted therapy
combining zoledronate with fluvastatin or atorvastatin for patients
with metastatic renal cell carcinoma. Clin Genitourin Cancer.
9:81–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
López-Aguilar E, Sepúlveda-Vildósola AC,
Betanzos-Cabrera Y, et al: Phase II study of metronomic
chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin
in the treatment of brain stem tumors in children. Arch Med Res.
39:655–662. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kornblau SM, Banker DE, Stirewalt D, et
al: Blockade of adaptive defensive changes in cholesterol uptake
and synthesis in AML by the addition of pravastatin to idarubicin +
high-dose Ara-C: a phase 1 study. Blood. 109:2999–3006. 2007.
|
|
78
|
Graf H, Jüngst C, Straub G, et al:
Chemoembolization combined with pravastatin improves survival in
patients with hepatocellular carcinoma. Digestion. 78:34–38. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Konings IR, van der Gaast A, van der Wijk
LJ, de Jongh FE, Eskens FA and Sleijfer S: The addition of
pravastatin to chemotherapy in advanced gastric carcinoma: a
randomised phase II trial. Eur J Cancer. 46:3200–3204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
McKenna WG, Weiss MC, Bakanauskas VJ, et
al: The role of the H-ras oncogene in radiation resistance and
metastasis. Int J Radiat Oncol Biol Phys. 18:849–859. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Miller AC, Kariko K, Myers CE, Clark EP
and Samid D: Increased radioresistance of EJras-transformed human
osteo-sarcoma cells and its modulation by lovastatin, an inhibitor
of p21ras isoprenylation. Int J Cancer. 53:302–307. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Rozados VR, Hinrichsen LI, McDonnell J and
Scharovsky OG: Lovastatin enhances in vitro radiation-induced
apoptosis of rat B-cell lymphoma cells. J Exp Clin Cancer Res.
24:55–61. 2005.PubMed/NCBI
|
|
83
|
Butt S, Butt T, Jirström K, et al: The
target for statins, HMG-CoA reductase, is expressed in ductal
carcinoma-in situ and may predict patient response to radiotherapy.
Ann Surg Oncol. 21:2911–2919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Mace AG, Gantt GA, Skacel M, Pai R, Hammel
JP and Kalady MF: Statin therapy is associated with improved
pathologic response to neoadjuvant chemoradiation in rectal cancer.
Dis Colon Rectum. 56:1217–1227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Werner M, Sacher J and Hohenegger M:
Mutual amplification of apoptosis by statin-induced mitochondrial
stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br
J Pharmacol. 143:715–724. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Holstein SA and Hohl RJ: Interaction of
cytosine arabinoside and lovastatin in human leukemia cells. Leuk
Res. 25:651–660. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Lishner M, Bar-Sef A, Elis A and Fabian I:
Effect of simvastatin alone and in combination with cytosine
arabinoside on the proliferation of myeloid leukemia cell lines. J
Investig Med. 49:319–324. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Soma MR, Pagliarini P, Butti G, Paoletti
R, Paoletti P and Fumagalli R: Simvastatin, an inhibitor of
cholesterol biosynthesis, shows a synergistic effect with
N,N′-bis(2-chloroethyl)-N-nitrosourea and β-interferon on human
glioma cells. Cancer Res. 52:4348–4355. 1992.PubMed/NCBI
|
|
89
|
Wang W, Collie-Duguid E and Cassidy J:
Cerivastatin enhances the cytotoxicity of 5-fluorouracil on
chemosensitive and resistant colorectal cancer cell lines. FEBS
Lett. 531:415–420. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Katz MS, Minsky BD, Saltz LB, Riedel E,
Chessin DB and Guillem JG: Association of statin use with a
pathologic complete response to neoadjuvant chemoradiation for
rectal cancer. Int J Radiat Oncol Biol Phys. 62:1363–1370. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Brennan DJ, Brandstedt J, Rexhepaj E, et
al: Tumour-specific HMG-CoAR is an independent predictor of
recurrence free survival in epithelial ovarian cancer. BMC Cancer.
10:1252010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lipkin SM, Chao EC, Moreno V, et al:
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase
modifies the chemo-preventive activity of statins for colorectal
cancer. Cancer Prev Res. 3:597–603. 2010. View Article : Google Scholar
|
|
93
|
Yu CY, Theusch E, Lo K, et al: HNRNPA1
regulates HMGCR alternative splicing and modulates cellular
cholesterol metabolism. Hum Mol Genet. 23:319–332. 2014. View Article : Google Scholar
|
|
94
|
Sławińska-Brych A, Zdzisińska B and
Kandefer-Szerszeń M: Fluvastatin inhibits growth and alters the
malignant phenotype of the C6 glioma cell line. Pharmacol Rep.
66:121–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yongjun Y, Shuyun H, Lei C, Xiangrong C,
Zhilin Y and Yiquan K: Atorvastatin suppresses glioma invasion and
migration by reducing microglial MT1-MMP expression. J
Neuroimmunol. 260:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Crosbie J, Magnussen M, Dornbier R,
Iannone A and Steele TA: Statins inhibit proliferation and
cytotoxicity of a human leukemic natural killer cell line. Biomark
Res. 1:332013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Al-Haidari AA, Syk I and Thorlacius H:
HMG-CoA reductase regulates CCL17-induced colon cancer cell
migration via geranylgeranylation and RhoA activation. Biochem
Biophys Res Commun. 446:68–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ishikawa S, Hayashi H, Kinoshita K, et al:
Statins inhibit tumor progression via an enhancer of zeste homolog
2-mediated epigenetic alteration in colorectal cancer. Int J
Cancer. 135:2528–2536. 2014. View Article : Google Scholar :
|
|
99
|
Chang HL, Chen CY, Hsu YF, et al:
Simvastatin induced HCT116 colorectal cancer cell apoptosis through
p38MAPK-p53-survivin signaling cascade. Biochim Biophys Acta.
1830:4053–4064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Rentala S, Chintala R, Guda M, Chintala M,
Komarraju AL and Mangamoori LN: Atorvastatin inhibited
Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK)
mediated adhesion and differentiation of
CD133+CD44+ prostate cancer stem cells.
Biochem Biophys Res Commun. 441:586–592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Peng X, Li W, Yuan L, Mehta RG, Kopelovich
L and McCormick DL: Inhibition of proliferation and induction of
autophagy by atorvastatin in PC3 prostate cancer cells correlate
with downregulation of Bcl2 and upregulation of miR-182 and p21.
PLoS One. 8:e704422013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Al-Husein B, Goc A and Somanath PR:
Suppression of interactions between prostate tumor cell-surface
integrin and endothelial ICAM-1 by simvastatin inhibits
micrometastasis. J Cell Physiol. 228:2139–2148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Fang Z, Tang Y, Fang J, et al: Simvastatin
inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK
and JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Islam M, Sharma S, Kumar B and Teknos TN:
Atorvastatin inhibits RhoC function and limits head and neck cancer
metastasis. Oral Oncol. 49:778–786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Yu X, Pan Y, Ma H and Li W: Simvastatin
inhibits proliferation and induces apoptosis in human lung cancer
cells. Oncol Res. 20:351–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Pelaia G, Gallelli L, Renda T, et al:
Effects of statins and farnesyl transferase inhibitors on ERK
phosphorylation, apoptosis and cell viability in non-small lung
cancer cells. Cell Prolif. 45:557–565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Chen J, Liu B, Yuan J, et al: Atorvastatin
reduces vascular endothelial growth factor (VEGF) expression in
human non-small cell lung carcinomas (NSCLCs) via inhibition of
reactive oxygen species (ROS) production. Mol Oncol. 6:62–72. 2012.
View Article : Google Scholar
|
|
108
|
Guterres FA, Martinez GR, Rocha ME and
Winnischofer SM: Simvastatin rises reactive oxygen species levels
and induces senescence in human melanoma cells by activation of
p53/p21 pathway. Exp Cell Res. 319:2977–2988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Pich C, Teiti I, Rochaix P, et al: Statins
reduce melanoma development and metastasis through MICA
overexpression. Front Immunol. 4:622013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Gopalan A, Yu W, Sanders BG and Kline K:
Simvastatin inhibition of mevalonate pathway induces apoptosis in
human breast cancer cells via activation of JNK/CHOP/DR5 signaling
pathway. Cancer Lett. 329:9–16. 2013. View Article : Google Scholar
|
|
111
|
Park YH, Jung HH, Ahn JS and Im YH: Statin
induces inhibition of triple negative breast cancer (TNBC) cells
via PI3K pathway. Biochem Biophys Res Commun. 439:275–279. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhao Z, Cao X, Pan Y, Sha S, Zhao T and
Zhang T: Simvastatin downregulates HER2 via upregulation of PEA3 to
induce cell death in HER2-positive breast cancer cells. Oncol Res.
20:187–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Qi XF, Zheng L, Lee KJ, et al: HMG-CoA
reductase inhibitors induce apoptosis of lymphoma cells by
promoting ROS generation and regulating Akt, Erk and p38 signals
via suppression of mevalonate pathway. Cell Death Dis. 4:e5182013.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zeng M, Gu WY, Jiang TX, et al: Effects of
simvastatin on PI3K/AKT signaling pathway in human acute monocytic
leukemia cell line SHI-1. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
20:268–272. 2012.(In Chinese). PubMed/NCBI
|
|
115
|
Yang SS, Li R, Qu X, Fang W and Quan Z:
Atorvastatin decreases Toll-like receptor 4 expression and
downstream signaling in human monocytic leukemia cells. Cell
Immunol. 279:96–102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Shi J, Zhu J, Zhao H, Zhong C, Xu Z and
Yao F: Mevalonate pathway is a therapeutic target in esophageal
squamous cell carcinoma. Tumour Biol. 34:429–435. 2013. View Article : Google Scholar
|
|
117
|
Ma L, Niknejad N, Gorn-Hondermann I,
Dayekh K and Dimitroulakos J: Lovastatin induces multiple stress
pathways including LKB1/AMPK activation that regulate its cytotoxic
effects in squamous cell carcinoma cells. PLoS One. 7:e460552012.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB
and Guan YY: Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in
simvastatin induced S-phase cell cycle arrest and apoptosis in
multiple myeloma cells. Eur J Pharmacol. 670:356–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Araki M, Maeda M and Motojima K:
Hydrophobic statins induce autophagy and cell death in human
rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. Eur
J Pharmacol. 674:95–103. 2012. View Article : Google Scholar
|
|
120
|
Liu H, Wang Z, Li Y, Li W and Chen Y:
Simvastatin prevents proliferation and bone metastases of lung
adenocarcinoma in vitro and in vivo. Neoplasma. 60:240–246. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Liao J, Chung YT, Yang AL, et al:
Atorvastatin inhibits pancreatic carcinogenesis and increases
survival in
LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
Mol Carcinog. 52:739–750. 2013. View Article : Google Scholar
|
|
122
|
Vitols S, Angelin B and Juliusson G:
Simvastatin impairs mitogen-induced proliferation of malignant
B-lymphocytes from humans - in vitro and in vivo studies. Lipids.
32:255–262. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Higgins MJ, Prowell TM, Blackford AL, et
al: A short-term biomarker modulation study of simvastatin in women
at increased risk of a new breast cancer. Breast Cancer Res Treat.
131:915–924. 2012. View Article : Google Scholar
|
|
124
|
Bansal D, Undela K, D’Cruz S and Schifano
F: Statin use and risk of prostate cancer: a meta-analysis of
observational studies. PLoS One. 7:e466912012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Park HS, Schoenfeld JD, Mailhot RB, et al:
Statins and prostate cancer recurrence following radical
prostatectomy or radiotherapy: a systematic review and
meta-analysis. Ann Oncol. 24:1427–1434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Singh PP and Singh S: Statins are
associated with reduced risk of gastric cancer: a systematic review
and meta-analysis. Ann Oncol. 24:1721–1730. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
van der Spek E, Bloem AC, Sinnige HA and
Lokhorst HM: High dose simvastatin does not reverse resistance to
vincris-tine, adriamycin, and dexamethasone (VAD) in myeloma.
Haematologica. 92:e130–e131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Han JY, Lim KY, Yu SY, Yun T, Kim HT and
Lee JS: A phase 2 study of irinotecan, cisplatin, and simvastatin
for untreated extensive-disease small cell lung cancer. Cancer.
117:2178–2185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Kim WS, Kim MM, Choi HJ, et al: Phase II
study of high-dose lovastatin in patients with advanced gastric
adenocarcinoma. Invest New Drugs. 19:81–83. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lazzeroni M, Guerrieri-Gonzaga A, Serrano
D, et al: Breast ductal lavage for biomarker assessment in high
risk women: rationale, design and methodology of a randomized phase
II clinical trial with nimesulide, simvastatin and placebo. BMC
Cancer. 12:5752012. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Kawata S, Yamasaki E, Nagase T, et al:
Effect of pravastatin on survival in patients with advanced
hepatocellular carcinoma. A randomized controlled trial. Br J
Cancer. 84:886–891. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Lersch C, Schmelz R, Erdmann J, et al:
Treatment of HCC with pravastatin, octreotide, or gemcitabine - a
critical evaluation. Hepatogastroenterology. 51:1099–1103.
2004.PubMed/NCBI
|
|
133
|
Knox JJ, Siu LL, Chen E, et al: A Phase I
trial of prolonged administration of lovastatin in patients with
recurrent or metastatic squamous cell carcinoma of the head and
neck or of the cervix. Eur J Cancer. 41:523–530. 2005. View Article : Google Scholar : PubMed/NCBI
|
